DNA vaccination with a gene encoding Toxoplasma gondii Deoxyribose Phosphate Aldolase (TgDPA) induces partial protective immunity against lethal challenge in mice

Abstract

BackgroundToxoplasma gondii is an obligate intracellular parasite that causes a pathological status known as toxoplasmosis, which has a huge impact on human and animal health. Currently, the main control strategy depends on the usage of drugs that target the acute stage of the infection, however, drawbacks were encountered while applying this method; therefore, development of an alternative effective method would be important progress. Deoxyribose Phosphate Aldolase (TgDPA) plays an important role supporting cell invasion and providing energy for the parasite.MethodsTgDPA was expressed in Escherichia coli and the purified recombinant protein was used to immunize rats. The antibodies obtained were used to verify in vitro expression of TgDPA. The vector pVAX1 was utilized to formulate a DNA vaccine designated as pTgDPA, which was used to evaluate the immunological changes and the level of protection against challenge with the virulent RH strain of T. gondii.ResultsDNA vaccine, TgDPA revealed that it can induce a strong humoral as well as cellular mediated response in mice. These responses were a contribution of TH1, TH2 and TH17 type of responses. Following challenge, mice immunized with TgDPA showed longer survival rates than did those in control groups.ConclusionsFurther investigation regarding TgDPA is required to shed more light on its immunogenicity and its possible selection as a vaccine candidate.

The Molecular Characterization and Immunity Identification of Rhoptry Protein 22 of Toxoplasma gondii as a DNA Vaccine Candidate Against Toxoplasmosis

“…All animals in three test groups were subjected to three intramuscular injections containing 100 μg of recombined plasmids, empty vectors or an equal volume of PBS separately at zero, second, and fourth weeks (Hassan et al. ; Zhu et al. ).…”

“…Initially, the plasmid was subjected to dilution and suspension using sterilized PBS to a final concentration of 1 lg/ll. All animals in three test groups were subjected to three intramuscular injections containing 100 lg of recombined plasmids, empty vectors or an equal volume of PBS separately at zero, second, and fourth weeks (Hassan et al 2014a;Zhu et al 2017). The animals in the negative control group did not receive any inoculation.…”

Toxoplasma gondii virus‐like particle vaccination alleviates inflammatory response in the brain upon T gondii infection

“…To date, several studies involving inactivated, attenuated, DNA and protein vaccines have been conducted to develop an effective T gondii vaccine 6‐8 . In spite of these efforts, vaccine incorporating the aforementioned strategies failed to provide sufficient protection in mice.…”

Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii

“…However, the drug application has produced toxic side effects and caused re-infection [5–7]. Thus, an alternative control strategy for toxoplasmosis is urgently needed.…”